Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMR analysis of drug treatments for primary microvascular angina
ChiCTR1900025319Phase 4Not yet recruiting
- Sponsor
- Hangzhou Red Cross Hospital
- Start
- Oct 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of diltiazem, beraprost and nicorandil in microvascular angina (MVA) (4 arms), sponsored by Hangzhou Red Cross Hospital. Primary endpoints: Cardiovascular magnetic resonance, von Willebrand factor and 1 more. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
diltiazemberaprostnicorandil
03
Conditions
microvascular angina (MVA)
Beyond the preview
Go deeper on ChiCTR1900025319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025319.